I am also still very positive on Vivus. Vivus is very close to getting some news from the EMA regarding its appeal of the Qsymia (Qsiva) decision for the EU. As you may remember, the EMA gave Vivus a negative opinion on Qsiva back in October 2012. Vivus did file an appeal of that decision, and the appeal will be decided on by the EMA soon.
Vivus will probably miss on the earnings numbers for Q4 2012, but Vivus is looking very positive on other measures. Prescription numbers are continuing to grow, and the scripts will grow even stronger after:
1. The amended Qsymia REMS are approved by the FDA to allow Qsymia scripts to be filled at local neighborhood retail pharmacies instead of through the national mail order pharmacies.
2. More health insurance companies (payers) agree to cover the cost of Qsymia.
3. A Stendra commercial partnership deal for the USA market is finalized and signed.
4. Stendra (Spedra) is approved by the EMA in the first half of 2013.